Bharat Biotech’s intranasal vaccine ‘iNCOVACC’ receives CDSCO approval under restricted use

The Central Drugs Standard Control Organisation (CDSCO) gave its nod to the vaccine for use as both primary series as well as a heterologous booster.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Biyrp9A
via IFTTT